Taiho Pharmaceutical, a specialty pharmaceutical company headquartered in Tokyo, plans to use Medidata Rave to conduct a Phase III trial for cervical cancer therapy in Japan, Taiwan, and South Korea.
Taiho anticipates that the company will effectively benefit from Medidata’s global contract research organization (CRO) partners who also work with Taiho. Because these partners are familiar with the Rave EDC system, outsourcing studies to these CROs will enable faster study starts, smooth implementations, easier data transfer and compatibility during trials.
Taiho also expects that investigators and data managers will experience reliability from the Rave system operations and Medidata’s training and professional staff services.
Tarek Sherif, CEO of Medidata Solutions, said: “As we further extend our reach in the Asia-Pacific region through our customers and CRO partners, we will continue to benefit from relationships with companies like Taiho that share our vision of implementing and conducting the most efficient clinical trials on a global scale.”